The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...